Form 10-K
DEF 14A
Teva Pays $420 Million to End Generic-Drug Securities Suit (1)
DEF 14A
DEF 14A
DEF 14A
DEF 14A
Teva won't say whether R&D cuts include layoffs; Cipla inks deal for Iranian plant; | Fierce Pharma
As U.S. Domestic Issuer, Teva Reveals Top Stock Owners | Ctech
DEF 14A
Stock Forecast Based On a Predictive Algorithm | I Know First |Stock Forecast: Teva Shares Rally After Buffet Announces His Doubled Position in Teva Stock
Teva Investor Relations on the App Store
DEF 14A
Teva announces $519 million FCPA settlement | The FCPA Blog
DEF 14A
Stock Forecast Based On a Predictive Algorithm | I Know First |Stock Forecast: Teva Shares Rally After Buffet Announces His Doubled Position in Teva Stock
DEF 14A
Form 10-K
DEF 14A
TEVA PHARMACEUTICAL INDUSTRIES LTD Form 10-Q Quarterly Report Filed 2022-05-03
Teva Pharma reserves $520 million for FCPA settlement | The FCPA Blog
Teva Investor Relations by Teva Pharmaceuticals USA, Inc.
DEF 14A
Teva Investor Relations on the App Store
DEF 14A
DEF 14A
